ARTLifeLine: Assisted Reproduction Technology (ART) Family Health and Development Trajectory Cohort (ARTLL)
NCT ID: NCT06786871
Last Updated: 2025-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
100000 participants
OBSERVATIONAL
2025-01-20
2043-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. On the basis of the assisted reproduction birth cohort and related research established by the team in the early stage, further expand the construction of the "tracking cohort of familial health and development using assisted reproduction", combine emerging technologies such as cross-database linking and integration, multi-omics sequencing and classical cohort research design, and carry out long-term longitudinal follow-up across generations, covering the whole life cycle and health in multi-dimension.
2. Build a disease risk prediction model for pregnant women and children with assisted reproduction.
3. Delineate the growth curve and neurobehavioral development trajectory of assisted reproductive offspring at different stages.
4. Evaluate the adolescent fertility potential and risk factors of assisted reproductive offspring.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Machine Learning and Pregnancy Success Prediction in Fertility Treatments
NCT06884930
St Mary's Assisted Reproductive Technology and Cardiometabolic Health: Modifiable Targets for Multimorbidity Prevention (START-HEALThY)
NCT07173569
Assessment of Some Metabolic and Hematological Markers in Women Exposed to in Vitro Fertilization
NCT06812663
Health in Childhood Following Assisted Reproductive Technology
NCT03719703
Stress in Couples Undergoing Assisted Reproduction Technology With Different Cycles and Its Impact on Pregnancy Outcomes
NCT05055245
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Build a risk prediction model for reproductive women and children in assisted reproduction, and identify potential molecular markers with high predictive value to provide epidemiological evidence clues for further basic mechanism research.
Analyze the health status of natural conception versus assisted reproduction pregnant women and children, growth and developmental curves of fetuses during pregnancy, and early neurobehavioral development levels of children after birth.
2. Medium to Long-Term Research Objectives (Future Research Directions of the Cohort):
Systematically evaluate the long-term effects of infertility and assisted reproductive treatments on the physiological, psychological, individual, and family development of parents and offspring.
Collaborate and share data with other domestic and international health cohorts or databases related to assisted reproduction, to compare and analyze the long-term safety of various assisted reproductive technologies on the health of infertile couples and their offspring.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Couples who have had or plan IVF fertility treatment and their offsprings
Have performed or plan to undergo IVF fertility treatment; Paper or electronic medical records during fertility treatment are available; Obtain informed consent from the research subject or guardian of the minor
IVF treatment
Methods or procedures for the in vitro processing of human oocytes, sperm, or embryos for fertility purposes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IVF treatment
Methods or procedures for the in vitro processing of human oocytes, sperm, or embryos for fertility purposes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
0 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jie Qiao, PhD
Role: STUDY_CHAIR
Peking University Third Hospital
Rong Li, PhD
Role: STUDY_DIRECTOR
Peking University Third Hospital
Wei Yuan, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Tongyan Han, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Liying Yan, PhD
Role: STUDY_DIRECTOR
Peking University Third Hospital
Yuanyuan Wang, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Rui / Yang, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Xiaohui / Zhu, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Lian / Chen, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Meihua / Piao, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Yunpu / Cui, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Yanan / Tang, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Chunling / Huang, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Chunmei / Zhang, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Linlin / Wang, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Ningning / Pan, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Huifeng Shi, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Tianchen / Wu, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Wanning / Qiu, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Jinfang / Yuan, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Hui / Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Qingqing Wang
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Meng Qin
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Ying Kuo
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Wenxi Zhang
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Shuo Guan
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Siming Jiang
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Fei Kong
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Tian Tian, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Lixue Chen
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Yu Fu
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Fang Liu
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University Third Hospital, Beijing, China
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M2023095
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.